Skip to main content

Table 4 Differences in the cytokine levels at day -7 and day + 14 for HSCT between the chronic extensive GVHD group and the other group

From: The soluble VCAM-1 level is a potential biomarker predicting severe acute graft versus host disease after allogeneic hematopoietic cell transplantation

 

day -7a

 

day +14a

 

Cytokine, mean ± SE

Extensive chronic GVHD (n = 10)

Othersb (n = 20)

P-value*

Extensive chronic GVHD (n = 10)

Othersb (n = 20)

P-value*

β2- MG, ng/ml

4488.3 ± 842.7

4399.7 ± 661.4

0.746

5559.5 ± 525.7

5697.3 ± 699.6

0.983

sVCAM-1, ng/ml

1171.7 ± 154.7

973.3 ± 88.5

0.328

1770.8 ± 144.1

1536.7 ± 110.4

0.214

PF4, ng/ml

389.2 ± 50.7

415.1 ± 34.1

0.681

360.3 ± 45.5

290.7 ± 30.6

0.198

TNFSF-14, ng/ml

36.9 ± 5.2

32.1 ± 3.7

0.286

32.3 ± 4.8

27.3 ± 2.8

0.307

  1. HSCT Allogeneic hematopoietic stem cell transplantation, GVHD Graft versus host disease, SE Standard error of the mean
  2. aThe timepoint of the serum cytokine measurement in relation to the HSCT
  3. bOthers included patients with limited chronic graft versus host disease (GVHD) and those with no chronic GVHD
  4. *Mann-Whitney U test
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us